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Available online 5 July 2011AbstractPseudomonas aeruginosa is a relevant opportunistic pathogen involved in nosocomial infections that frequently shows low antibiotic
susceptibility. One of its virulence factors is associated with the ability to adhere to surfaces and form virulent biofilms. This work describes the
isolation and characterization of lytic phages capable of infecting antibiotic-resistant P. aeruginosa strains. In addition, characterization of
P. aeruginosa biofilms and the potential of newly isolated phages for planktonic and biofilm control was accessed. According to the results, the
isolated phages showed different spectra of activity and efficiency of lysis. Four broad lytic phages were selected for infection of planktonic
cells; however, despite their broad range of activity, two of the selected phages failed to efficiently control planktonic cultures. Therefore, only
two phages (phiIBB-PAA2 and phiIBB-PAP21), highly capable of causing strong biomass reduction of planktonic cells, were tested against 24 h
biofilms using a m.o.i. of 1. Both phages reduced approximately 1e2 log the biofilm population after 2 h of infection and reduction was further
enhanced after 6 h of biofilm infection. However, biofilm cells of P. aeruginosa PAO1 acquired resistance to phiIBB-PAP21; consequently, an
increase in the number of cells after 24 h of treatment was observed. Conversely, phage phiIB-PAA2 for P. aeruginosa ATCC10145 continued to
destroy biofilm cells, even after 24 h of infection. In these biofilms, phages caused a 3 log reduction in the number of viable counts of biofilm
cells.
 2011 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
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Pseudomonas aeruginosa is an ubiquitous organism which
has emerged as a major threat in the hospital environment.
This bacterium is the most frequently isolated Gram-negative
organism in bloodstream and wound infections, pneumonia
and intra-abdominal and urogenital sepsis, and is a serious
problem, infecting immunocompromised patients with cystic
fibrosis (CF), severe burns, cancer, AIDS, etc. (Driscoll et al.,
2007; Page and Heim, 2009). One of the most worrying
characteristics of this bacterium is its low antibiotic* Corresponding author.
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0923-2508/$ - see front matter  2011 Institut Pasteur. Published by Elsevier Ma
doi:10.1016/j.resmic.2011.06.010susceptibility, which can be attributed to a concerted action of
multidrug efflux pumps with chromosomally-encoded antibi-
otic resistance genes and the low permeability of the bacterial
cellular envelopes (Lambert, 2002).
Overuse of antibiotics has also significantly increased the
emergence of antimicrobial multiresistant bacteria; conse-
quently, treatment of most chronic P. aeruginosa infections
with antibiotics is notoriously difficult (Cunha, 2002; Lambert,
2002). Additionally, P. aeruginosa has an innate ability to
adhere to surfaces and form virulent biofilms particularly
difficult to eradicate (Drenkard, 2003; Mah et al., 2003;
Stewart and Costerton, 2001). Biofilm formation is an
important bacterial survival strategy and, in humans, biofilms
are responsible for numerous pathologies usually associated
with use of medical devices (Azeredo and Sutherland, 2008;
Donlan, 2002; O’Toole et al., 2000). Thus, new alternativesson SAS. All rights reserved.
Table 1
Characterization of the different P. aeruginosa phage plaques.
Host Phage (phiIBB-.) Diameter (mm)a Turbidity Halo
ATCC 10145 PAA2 1 T e
CECT 111 PAC222 2 T e
PAC2211 1.5 T e
PAC2212 1 C þ
PAC111 2.5 C þ
PAC23 1.5 T e
PAC24 4 C e
PAO 1 PAP2222 2 C þ (large)
PAP21 1 T e
PAP2221 2.5 C þ (large)
PAP221 1.5 T e
PAP121 2 C e
CLIN PACL212 1 C þ
PACL211 3 C þ
PACL22 3 C þ
PACL11 1 T e
PACL12 2 T e
T: turbid; C: clear; D presence of halo; - no visible halo.
a Mean diameter of 5 different phage plaques measured.
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worldwide medical and scientific community. Bacteriophages
(phages) are the natural enemies of bacteria and might
represent one attractive solution to this problem (Clark and
March, 2006; Joerger, 2003; Sulakvelidze, 2005).
Phage therapy is based on the use of lytic phages to combat
bacterial infections, including multidrug-resistant bacteria,
and has many advantages comparated to antibiotics: they are
very specific and efficient for their target bacteria, which
reduces destruction of the host’s natural flora; they are not
pathogenic for man; and they persist only as long as the tar-
geted bacteria are present (Azeredo and Sutherland, 2008;
Clark and March, 2006; Matsuzaki et al., 2005; Skurnik and
Strauch, 2006).
Here we describe the isolation and characterization of novel
phages for P. aeruginosa and their application to planktonic
cultures and biofilms. The main goal is to determine phage
potential to control these two types of cells.
2. Materials and methods2.1. Bacterial strains and culture conditionsThirty-five strains of P. aeruginosa were used in this work:
4 strains for isolation of phages e ATCC 10145, CECT 111,
PAO1 and a clinical isolate (CLIN) (isolated from an endo-
scope, Rouen, France) e and 31 strains for evaluating the lytic
spectra of the isolated phages. These 31 strains were clinical
isolates provided by the Hospital de Braga (Braga, Portugal).
Bacteria were grown at 37 C in tryptic soy broth (TSB,
Merck) or in tryptic soy agar (TSA, Merck). Biofilm assays
were performed using yeast peptone dextrose (YPD - 10 g l1
yeast extract, 20 g l1 peptone, 20 g l1 dextrose).2.2. Isolation of phagesBacteriophages were isolated from 2 hospital effluents
provided by the Hospital de São João (Porto, Portugal). These
effluents were enriched with 4 bacterial hosts (ATCC 10145,
CECT 111, PAO1 and a clinical isolate) in 2  TSB medium.
This solution was incubated (37 C, 120 rpm) for 48 h and
then centrifuged to collect supernatant for spot tests indicative
of the existence of phage(s). Each inhibition halo was further
purified with toothpicks and paper to isolate all different
phages. All morphologically different phage plaques were
purified until de Petri plates presented a single plaque
morphology. Five similar plaques of each isolated phage were
measured and characteristics are presented in Table 1.2.3. Production of phagesThe production of phages in Petri plates consists of
immersing a paper strip in a solution containing phage and
passing it on a top-agar layer containing the proper bacterial
strain. The plates were incubated for 16e18 h at 37 C; then,
3 ml of SM buffer (5.8 g l1 NaCl, 2 g l1 MgSO4.7H2O,
50 ml l1 1M-tris-HCl pH 7.5) were added. The plates wereplaced under agitation (120 rpm) at 4 C for 16e18 h; after-
wards, liquid and top-agar were collected, centrifuged and the
supernatant was filtrated (0.2 mm).2.4. Selection of phagesThe selection of the 4 best phages (one for each host) was
done according to results of lytic spectra. To evaluate lytic
spectra of all isolated phages, they were tested against 35
strains of P. aeruginosa. One drop of each serial diluted phage
suspension, with titers of about 104 to 107 PFU ml1, was
placed on the different bacterial lawns and incubated overnight
at 37 C. The following day, the susceptibility of each host to
the different phages was evaluated.2.5. Infection of planktonic cellsInfection of planktonic cells was done at two different
stages of bacterial growth e exponential and stationary pha-
ses. To induce planktonic cell infections at the stationary
stage, the 4 hosts were inoculated overnight in TSB medium at
37 C (120 rpm). The resulting cell suspensions were diluted
with TSB medium to obtain an optical density (OD600nm) of
approximately 0.75, which corresponds to approximately
1.32  109, 1.11  109, 1.28  109 and 8.71  108 CFU ml1
of P. aeruginosa ATCC 10145, CECT 111, CLIN and PAO1,
respectively. To carry out planktonic cell infection at expo-
nential stage, an overnight pre-inoculum was used to inoculate
100 ml of fresh TSB medium, which were allowed to grow to
an optical density (OD600nm) of 0.5, which corresponds to
approximately 8.63  108, 7.42  108, 8.67  108 and
6.21  108 CFU ml1 of P. aeruginosa ATCC 10145, CECT
111, CLIN and PAO1, respectively. The suspensions were
centrifuged and resuspended in fresh TSB media in obtain an
OD600nm of 0.75 which allows better comparison of the two
different assays performed. In all experiments, 125 ml of
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hosts in order to obtain a multiplicity of infection (m.o.i.) of 1.
The control experiments were performed with SM buffer
instead of phages. The infection of planktonic cell assays were
performed in 96-well microtiter plates. The plates were placed
into an orbital incubator (120 rpm) at 37 C and the optical
density (OD600nm) was regularly read. Three independent
experiments were performed in duplicate.2.6. Biofilm formationBased on phage infection experiments on planktonic cells,
only P. aeruginosa ATCC 10145 and PAO1 strains were used
in biofilm assays. Biofilm formation was carried out in 24-well
microplates containing 1 ml of YPD medium and 10 ml of
cellular suspension with an OD600nm of 1.0 which corresponds
to approximately 1.9  109 and 1.1  109 CFU ml1,
respectively. Biofilms were formed for 24 and 48 h with
medium renewal every 12 h. The plates were incubated at
37 C in an orbital shaker (120 rpm). Three independent
experiments were performed in duplicate.2.7. Crystal violet assayTotal biomass attached to each well was measured by
crystal violet assay. First, the wells were washed twice with
a saline solution (0.9% NaCl (Merck) in distilled water)) and
then biofilms were fixed with 1 ml of methanol (Merck) for
15 min. After this time, methanol was removed and to each
well was added 1 ml of crystal violet (1% v/v, Merck) for
5 min. The wells were then washed with water, and 1 ml of
acetic acid (33% v/v, Merck) was added to dissolve the stain.
The eluted stain was placed in a 96-well microtiter plate and
its absorbance was read by an ELISA reader at 570 nm. Two
independent experiments were performed in duplicate.2.8. XTT reduction assayThe determination of biofilm cellular activity was measured
by the XTT reduction assay. Biofilms were washed twice with
a saline solution (0.9% NaCl (Merck) in distilled water)) and
then 1 ml of XTT (200 mg l1, Sigma) solution plus PMS
(20 mg l1, Sigma) was added to each well. The plates were
incubated in the dark at 37 C for 3 h. After this time, the
solution was removed from each well and placed in a 96-well
microtiter plate to determine its absorbance at 490 nm. Two
independent experiments were performed in duplicate.2.9. Biofilm infectionBiofilm infection was done with two different phages e
phiIBB-PAA2 and phiIBB-PAP21. After 24 h of biofilm
formation, all medium and planktonic bacteria were removed
from each well and washed with fresh YPD medium.
Following that, 500 ml of fresh YPD medium and 500 ml of
phage solution or 500 ml of SM buffer in the case of control
experiments were added. The m.o.i. used for both phageswas 1. The plates were incubated in an orbital shaker
(120 rpm) at 37 C and samples were taken after 2, 6 and 24 h
of infection for CFU and PFU counts. Three independent
experiments were performed in duplicate.2.10. CFU and PFU countsTo determine the amounts of bacteria present in biofilms,
CFU counts was performed using the microdrop technique.
Briefly, wells of the microplates were washed once with saline
solution (0.9% NaCl) to remove unattached bacteria and then
1 ml of fresh saline solution was added to each well and the
biofilm scraped with a cell scraper prior to sonication (5 min).
After this, the cellular suspension of each well was removed,
centrifuged (5 min, 9000 g, 4 C) and the pellet resuspended
in 1 ml of saline solution (0.9%). The samples were diluted in
saline solution (0.9%) and one drop (10 ml) was placed in
a Petri plate containing YPD solid medium and allowed to run
down the plate. Plates were incubated at 37 C for 16e18 h
and after CFUs were counted. For PFU counting, the small
drop method described by Mazzoco et al. with some modifi-
cations was used (Mazzocco et al., 2008). Briefly, 20 ml of
diluted phage solution were added to 20 ml of the overnight-
grown host and incubated for 15e20 min to allow phage
binding to the host. After this, 20 ml of sample was placed in
an agar plate and allowed to dry. Plates were incubated
overnight at 37 C. Three independent experiments were
performed in duplicate.2.11. Statistical analysisTo compare the amounts of viable cells present in biofilms,
analysis of variance (ANOVA single factor from MS Office)
was used. In all analyses performed, the confidence interval
used was 95%.
3. Results3.1. Phage characterizationInitially, 17 phages were isolated from hospital effluents by
enrichment with 4 strains of P. aeruginosa. Characteristics of
these phages were determined by the diameter and turbidity of
phage plaques and the presence of a halo (Table 1). From the
group of isolated phages, there were approximately the same
number of phages responsible for clear (9 phages) and turbid
(8 phages) plaques. Furthermore, some phages formed large
plaques (ex: phiIBB-PAC24) while others had more pinhole
characteristic (ex. phiIBB-PAP21) plaque morphology.
Furthermore, most isolated phages were non halo-generating
ones.
After characterizing the morphology of phage plaques,
newly isolated phages were also tested against altogether 35
antibiotic-resistant clinical and reference strains of P. aerugi-
nosa in order to study their lytic spectra (Table 2). Most phages
showed lytic activity against several isolates, even against
strains resistant to most of the 7 antibiotics tested, such as
Table 2
Lytic spectra of newly isolated phages against reference and clinical strains of P. aeruginosa.
Phage (phiIBB-.)
Host Antibioga PAP21 PAP121 PAP221 PAP2221 PAP2222 PAA2 PAC24 PAC23 PAC111 PAC222 PAC2211 PAC2212 PACL11 PACL12 PACL22 PACL211 PACL212
PAO 1 nd C T T T T e T C e C e T e T e e e
ATCC 10145 nd C C T C C T C C C T T C e e e e e
CECT 111 nd T e e e e T C C C T T C e e e e e
CLIN nd T T e T e T T T T T e e T T T T T
1 54 T C T C T C C C C C C C e C e e e
2 0 e T e e e C (RB) T T T T T T e e e e e
3 14 C e e e e C C C C C C C e e e e
4 0 C e C C T T T T T T e e e e e e e
5 14 C T C T T T C (RB) C (RB) C (RB) T T C (RB) T T T T T
6 0 C C C T T C (RB) C (RB) C (RB) C (RB) T T T C C e C C
7 29 C (RB) e e e e C (RB) C C C C T C (RB) e C e e e
8 0 C C C T e C C C (RB) C (RB) C (RB) e C e C e e e
9 0 e e e e e T T T T T T T e e e e e
10 43 e T T T e T T T e e T e T T T T e
11 57 C C C C C T T T T C C C e C e e e
12 86 C T T T T T T T T e e T C e C (RB) T T
13 14 e e e e T T C C C C C C e e e e e
14 14 e e e e e e T T e e e e e e e e e
15 0 e e e e e T T T e T T T e e e e e
16 0 C C C C C C (RB) C C T C T e e C e e T
17 86 C T e T C C (RB) C C C (RB) C e e e e e e e
18 29 C C C C (RB) C T e e T e e e e C (RB) e e e
19 71 e e e e e T T T e T e e e e e e e
20 0 T T T T T e e T e T T e T T T T T
21 0 T T T T C T T e T e T T C C e e T
22 0 T C C C T e e e e e T e e C e e e
23 14 T e T e T T T T T T e e e e e e e
24 14 T e e e e T T T e T e e e e e e e
25 86 C C C C C C C C T C T T e C e e e
26 0 C C C C C T C C (RB) T T T T e C e e e
27 0 T C T C C C C C T C T T e C e e e
28 14 T e e e e T T T T T T T e e e e e
29 0 T C T C C C (RB) T C (RB) T C (RB) e e e T e e e
30 nd T C C C C e e e e e e e e C e e e
31 nd T T T e T T T T T e T T T e T e T
% Infection 80.00 65.71 62.86 62.86 62.86 85.71 88.57 88.57 74.29 77.14 62.86 60.00 22.86 54.29 17.14 17.14 22.86
T: Turbid; C: Clear; C(RB): Clear with resistant bacteria; nd: not determined.





































802 D. Pires et al. / Research in Microbiology 162 (2011) 798e806isolate numbers 12, 17, 19 and 25, respectively. Phages isolated
for strain CECT 111 were shown to infect the highest number of
strains used in this study. Nevertheless, some phages, and
especially those isolated for the clinical strain of P. aeruginosa,
had a narrower spectrum of activity (ex. phiIBB-PACL22 and
phiIBB-PACL211) towards the tested isolates and therefore
were considered less efficient. Although only one phage was
isolated for the ATCC 10145 strain, phiIBB-PAA2 respectively,
this phage proved to have a broad spectrum of activity, infecting
85.71% of the tested strains (see Table 2).
After lytic spectrum assays, one phage for each host was
selected for use in planktonic and biofilm infection experi-
ments. The criterion used for this selection was the number of
strains that each phage was able to infect. Accordingly, the
selected phages were: phiIBB-PAA2, phiIBB-PAC23, phiIBB-
PACL12 and phiIBB-PAP21, respectively. These phages were
analysed by transmission electron microscopy (TEM) and
presented a head size of 58 nm and a tail of 12 nm  8 nm
characteristic of the Podoviridae family of phages (Fig. 1).3.2. Infection of planktonic cellsAfter phage selection and characterization, phage infection
experiments were performed in exponentially growing and
stationary cells (Fig. 2). The growth of the 4 different Pseu-
domonas strains varied considerably. Since this experiment
was performed using fresh media, an increase in optical
density of stationary phase cells was also observed. The 4
phage-host systems showed a clear difference in the infection
patterns of stationary and exponentially growing cells. Both
phages phiIBB-PAA2 and phiIBB-PAP21 infected exponen-
tially growing cells. Unlike phiIBB-PAP21, phage phiIBB-
PAA2, besides infecting exponential phase cells, was alsoFig. 1. Phage phiIBB-PAA2 observed by TEM. (Bar corresponds to 100 nm).capable of lysing stationary phase cells. The infection of both
stationary and exponential growth phase cells with phage
phiIBB-PAC23 caused only a minor reduction in OD.
Furthermore, strain CLIN continued to grow slowly even in
the presence of phage phiBB-PACL12. Despite the last two
mentioned phages, which were less efficient than phages
phiIBB-PAA2 and phiIBB-PAP21, there was a significant
difference in the infected cultures compared to the exponential
and stationary controls, performed with SM buffer instead of
the different phages.3.3. P. aeruginosa biofilm characteristics24- and 48-h-old P. aeruginosa biofilms were characterized
in terms of biomass quantity by CV staining, CFU counts, and
also through evaluation of metabolic activity by XTT reduction.
The medium in both biofilms was renewed every 12 h. Since
phages phiIBB-PACL12 and phiIBB-PAC23 were less effective
in lysing cells, only biofilms of P. aeruginosa ATCC 10145 and
PAO1were characterized for further infection experiments with
phages phiIBB-PAA2 and phiIBB-PAP21, respectively.
Biofilms of P. aeruginosa ATCC 10145 were characterized
by having a higher amount of biomass attached to the surface
of the 24 well-plate (Fig. 3A) than biofilms of P. aeruginosa
PAO 1. There were no significant differences in the amount of
total biomass existing in 24- and 48-h-old biofilms. In terms of
metabolic activity, XTT results showed that 24-h-old biofilms
of P. aeruginosa PAO 1 were more active than 48-h-old bio-
films of this strain; however, 24 and 48 h P aeruginosa ATCC
10145 biofilms resulted in similar values (Fig. 3B). The viable
counts of both strains in the studied biofilms were statistically
similar ( p ¼ 0.15). Furthermore, 24 h biofilms of P. aerugi-
nosa ATCC 10145 had a significantly higher ( p ¼ 0.025)
number of viable cells than biofilms formed for 48 h (Fig. 3C).
Although, 24 h biofilms of PAO1 presented more viable cells,
values compared to 48 h biofilms were not statistically
different ( p ¼ 0.29).3.4. Biofilm infectionPhage infection of P. aeruginosa ATCC 10145 and PAO1
was performed in 24 h biofilms (Fig. 4) due to the fairly
similar amounts of viable cells present in 24 and 48 h PAO1
and ATCC 10145 biofilms (as described above). According to
infection results, phage phiIBB-PAA2 gradually decreased the
numbers of viable cells present in the biofilms; already after
2 h, there was a statistically significant ( p ¼ 0.025) reduction
in viable cells, which was further enhanced after 6 and 24 h of
biofilm infection, achieving an almost 3-log reduction. Phage
phiIBB-PAP21 caused a considerably greater reduction
( p ¼ 0.0008) in P. aeruginosa PAO1 biofilm cells after 2 h of
infection compared to reduction of P. aeruginosa ATCC 10145
infected with phiIBB-PAA2. The reduction of P. aeruginosa
PAO1 biofilms due to phiIBB-PAP21 continued until 6 h of
biofilm treatment; however, biofilm cells acquired resistance
to the phage and consequently, the numbers of cells after 24 h
of infection increased.
Fig. 2. Infection of planktonic P. aeruginosa cultures with phages: A) phiIBB-PAA2 (ATCC 10145), B) phiIBB-PAP21 (PAO1), C) phiIBB-PAC23 (CECT 111),
and D) phiIBB-PACL12 (CLIN) in exponential and stationary growth using a MOI 1. Error bars represent standard deviations from 3 independent experiments
performed in duplicate.
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attached to the biofilms (and the surface of the well) as
measured by plaque-forming unit (PFU) counts. After 2 h of
infection, higher amounts of phage phiIBB-PAA2 than phage
phiIBB-PaP21 were observed entrapped in the biofilms.
Experiments performed in 24-well microtiter plates in the
absence of P. aeruginosa cells, showed that phiIBB-PAA2
attached more rapidly to the well substrata (data not shown).
This can explain the weaker reduction in the amount of viable
cells of P. aeruginosa ATCC 10145 by phage phiIBB-PAA2,
since phages attached to the substrata far from biofilm cells
will not cause their lysis. The number of phage phiIBB-PAA2
entrapped in the biofilms (and substrata) decreased throughout
the 24 h experiment by approximately 1.7 logs. Unlike phageFig. 3. Characterization of P. aeruginosa ATCC 10145 and PAO1 biofilms formed f
biofilm metabolic activity by XTT; C) enumeration of the number of viable cells
independent experiments performed in duplicate.phiIBB-PAA2, the amount of phiIBB-PAP21 phages adsorbed
increased until 6 h of infection. Nevertheless, as in phiIBB-
PAA2 experiments, also after 24 h of biofilm cell infection,
the number of phages attached was significantly lower.
The time for biofilm cell resistance toward phages was
compared with the resistance acquired by planktonic cells
(Fig. 5). After approximately 9e10 h of infection, planktonic
P. aeruginosa PAO1 cell cultures began to grow again. Both
colonies of planktonic and biofilm experiments were tested
with phage stock solution, and all showed resistance to
phiIBB-PAP21. Despite the lack of resistance of P. aeruginosa
ATCC 10145 biofilms after 24 h of exposure to phage phiIBB-
PAA2, acquisition of resistance by planktonic cultures to the
phage was observed.or 24 and 48 h. A) Biomass quantification using CV staining; B) evaluation of
present in the biofilms. The error bars represent standard deviations from 3
Fig. 4. Infection of P. aeruginosa ATCC 10145 and PAO1 biofilms with phages phiIBB-PAA2 and phiIBB-PAP21, respectively. A) Number of viable cells before
and after infection; B) number of phages (PFU) present in the biofilms; C) number of phages (PFU) released from infected biofilms. The error bars represent
standard deviations from 3 independent experiments performed in duplicate.
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The development of new alternatives to antibiotherapy for
eradication and control of virulent biofilms from surfaces,
mainly of medical devices, has become a great challenge in
the scientific community. Several studies have shown the
potential of use of phages to treat infectious diseases in
animals (Loc Carrillo et al., 2005; McVay et al., 2007; Nakai
and Park, 2002; Wagenaar et al., 2005) and humans (Weber-
Dabrowska et al., 1987, 2001), even those caused by
antibiotic-resistant bacteria (Weber-Dabrowska et al., 2003).
In the present study, 17 new phages for P. aeruginosa were
isolated from hospital effluents using three collection strainsFig. 5. Infection of P. aeruginosa ATCC 10145 and PAO1 planktonic cultures
with phages phiIBB-PAA2 and phiIBB-PAP21, respectively, using an m.o.i. of
1 for 25 h.and a clinical strain and they were tested for efficiency against
35 clinical strains. The least efficient isolated phages were
those with the clinical P. aeruginosa isolate as host, where the
percentages of strains infected varied between 17 and 54
percent, while the most efficient phages, those with CECT 111
as propagating strain, were capable of lysing approximately
60e89 percent of the clinical strains tested. These percentages
are significantly above those observed by Knezevic et al. for
19 newly isolated P. aeruginosa phages which were found to
be capable of killing up to 75.8 percent of 33 strains isolated
from humans (21), animals (1), the environment (10) and 1
culture strain (ATCC 9027) (Knezevic et al., 2009).
Based on the efficiency of killing clinical strains, four lytic
phages were selected for further characterization and used in
infection assays against planktonic and biofilm cells. Despite
the broad spectra of activity of the selected phages against
clinical P. aeruginosa isolates, infection experiments on
planktonic cultures showed, surprisingly, that two of them
failed to infect their hosts even at the ideal bacterial growth
phasedthe exponential phase. This suggests that, although
phages can be selected based on their broad activity, this does
not necessarily guarantee their effectiveness in controlling
their respective host population. Nevertheless, two of the used
phages, phages phiIBB-PAA2 and phiIBB-PAP21, were both
efficient towards exponential as well as stationary phase cells
and caused over a 50% reduction in initial OD. Yet phage
phiIBB-PAP21 revealed a slightly weaker ability to infect P.
aeruginosa PAO1 planktonic cells than phage phiIBB-PAA2
for strain ATCC 10145. It has been frequently reported, with
different phage-host systems, that there is reduced lysis when
805D. Pires et al. / Research in Microbiology 162 (2011) 798e806cells are near the stationary phase (Abedon and Yin, 2009;
Burch and Chao, 2004; Middelboe, 2000; Ricciuti, 1972;
Sillankorva et al., 2004). For instance, the T4 phage cannot
even produce a burst if Escherichia coli cells are in the
stationary phase (Delbrück, 1940). The main factors
accounting for reduction of lysis in stationary cells are: fewer
phage-adsorption sites, lower phage progeny per infection and
reduced cell lysis due to cell wall thickness or increased non-
viable infections (Weitz and Dushoff, 2008). Thus, our results
are extremely interesting, as they demonstrate that some, but
not all “T7-like” phages can be effective against stationary
phase cells.
It is not surprising that phage infection in planktonic cells is
more efficient than in biofilms due to biofilm architecture,
which prevents easy access by phages to the bacteria (Hanlon
et al., 2001). Due to the inefficient activity of phages phiIBB-
PACL12 and phiIBB-PAC23 against planktonic cultures, only
two phages, phiIBB-PAA2 and phiIBB-PAP21, were chosen
for P. aeruginosa biofilm control experiments. Both phages,
tested against 24 h biofilms, caused significant reduction on
biofilm cells already after 2 h of infection and the reduction
was further enhanced after 6 h of biofilm treatment, reaching
a reduction of almost 3 log by phage phiIBB-PAP21 and a 2
log reduction by phage phiIBB-PAA2. Although our approach
was different, viable cell reductions achieved were similar to
those reported by Fu et al., where P. aeruginosa phages were
used to prevent biofilm formation on hydrogel-coated catheter
surfaces. Accordingly, Fu et al., after 24 h, achieved a 2.84-log
lower number of viable cells on phage pre-treated catheters
than on untreated catheters (Fu et al., 2010).
Despite lower activity against planktonic cells, phage
phiIBB-PAP21 caused a stronger reduction in viable cells from
P. aeruginosa PAO1 biofilms after 2 and 6 h of treatment than
phage phiIBB-PAA2 in P. aeruginosa ATCC 10145 biofilms.
Similar reductions in viable cells have been observed for
Pseudomonas fluorescens phages (Sillankorva et al., 2004) and
there is only one work in the literature where complete erad-
ication of 24 h Enterobacter cloace biofilms by a combination
of 3 different phages was achieved (Tait et al., 2002). The
main difference between the two phages used in our work for
P. aeruginosa biofilm control experiments, concerns resistance
to phages. The interaction of phages and bacteria during long
periods of time can result in the emergence of phage-resistant
bacteria (Bohannan and Lenski, 2000; Buckling and Rainey,
2002). Biofilm cells of P. aeruginosa PAO1, the host of
phage phiIBB-PAP21, acquired resistance to the phage,
resulting in an increase in the number of cells after 24 h of
biofilm treatment. To evaluate the period when resistance
starts appearing in planktonic cultures, P. aeruginosa PAO1
planktonic cells infected with phage phiIBB-PAP21 showed
that resistance appeared after approximately 9e10 h of
infection, which is in accordance with biofilm results showing
the emergence of resistance between 6 and 24 h. On the other
hand, phage phiIBB-PAA2 continued to destroy biofilm cells
of P. aeruginosa ATCC 10145 and there was no evidence of
biofilm cells becoming resistant even after 24 h of phage
infection. Unlike experiments with P. aeruginosa ATCC10145 biofilms, assays performed with planktonic cells and
phage phiIBB-PAA2 resulted in increased resistance to this
phage. In 24 h P. aeruginosa ATCC 10145 biofilms, most
likely there are already some resistant phenotypes; however,
their growth is possibly slower and thus, non-randomly
selected and tested colonies showed resistance to phage
phiIBB-PAA2. Further studies will be performed to under-
stand and confirm the phenomenon of increased resistance of
planktonic cells, compared to biofilm cells.
Thus, this study reveals that both novel isolated phages
were capable of controlling P. aeruginosa biofilms; however,
short periods of treatment seem to be a better solution for
avoiding the emergence of phage-resistant hosts. In addition,
use of phage cocktails presented advantages over use of single
cells, since phages can be selected in such a way as to over-
whelm host resistance mutations.Acknowledgements
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